Study: Some anticoagulants more cost-effective than warfarin

04/10/2013 | MedPage Today (free registration)

The anticoagulants apixaban, dabigatran and rivaroxaban are more cost-effective than warfarin in the prevention of strokes among patients with nonvalvular atrial fibrillation, according to a study in Stroke: Journal of the American Heart Association. The costs analyzed in the review were associated with clinical events, visits with doctors, medicines, testing and adverse events.

View Full Article in:

MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC